We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Dose of reality

4 Dec 2014 By Kevin Allison

A pension fund adviser says the U.S. pharmacy chain is overpaying for the rest of its Swiss-based peer. The complaint is a little confusing, though concerns about risk seem valid. With a big shareholder and activist Jana already on board, the transaction will be tough to derail.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)